171 related articles for article (PubMed ID: 37526840)
1. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA
Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840
[TBL] [Abstract][Full Text] [Related]
2. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
[TBL] [Abstract][Full Text] [Related]
6. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
Reiss M; Büttel IC; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
[TBL] [Abstract][Full Text] [Related]
7. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.
Gluud C; Kubiak C; Whitfield K; Byrne J; Huemer KH; Thirstrup S; Libersa C; Barraud B; Grählert X; Dreier G; Geismann S; Kuchinke W; Temesvari Z; Blasko G; Kardos G; O'Brien T; Cooney M; Gaynor S; Schieppati A; de Andres F; Sanz N; Kreis G; Asker-Hagelberg C; Johansson H; Bourne S; Asghar A; Husson JM; Demotes-Mainard J
Trials; 2012 Mar; 13():27. PubMed ID: 22452964
[TBL] [Abstract][Full Text] [Related]
8. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
9. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
10. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
[TBL] [Abstract][Full Text] [Related]
11. Planning an Academic Clinical Trial.
Champion KM; Jones GR
Methods Mol Biol; 2015; 1317():287-313. PubMed ID: 26072413
[TBL] [Abstract][Full Text] [Related]
12. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
13. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
15. Issues with Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union.
Joyce K; Buljovcic Z; Rosic G; Kaszkin-Bettag M; Pandit A
Tissue Eng Part B Rev; 2023 Feb; 29(1):78-88. PubMed ID: 36062927
[TBL] [Abstract][Full Text] [Related]
16. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
17. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
18. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614
[TBL] [Abstract][Full Text] [Related]
19. RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation.
Guerriaud M; Kohli E
Front Med (Lausanne); 2022; 9():1012497. PubMed ID: 36325384
[TBL] [Abstract][Full Text] [Related]
20. Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States.
Ivaskiene T; Mauricas M; Ivaska J
Curr Stem Cell Res Ther; 2017; 12(1):45-51. PubMed ID: 27412678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
